CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major

Journal of Immunology

Volumn 168, Issue 8, 2002, Pages 3992-4000

  Belkaid, Yasmine ^a   Von Stebut, Esther ^a   Mendez, Susana ^a   Lira, Rosalia ^a   Caler, Elisabet ^a   Bertholet, Sylvie ^a   Udey, Mark C ^a   Sacks, David ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; LEISHMANIA MAJOR; MOUSE; NONHUMAN; PATHOGENESIS; PRIMARY IMMUNE RESPONSE; PRIORITY JOURNAL; PROMASTIGOTE; PROTOZOAL INFECTION; SKIN LEISHMANIASIS; T LYMPHOCYTE;

EID: 0037090268     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.168.8.3992     Document Type: Article

References (53)

1. Immunologic regulation of experimental cutaneous leishmaniasis. V. Characterization of effector and specific suppressor T cells
2. + T cells in the immunological control of experimentally induced murine cutaneous leishmaniasis
3. Administration of monoclonal anti-IFN-γ Abs in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major
4. Recombinant interleukin 12 cures mice infected with Leishmania major
5. Resolution of cutaneous leishmaniasis: Interleukin 12 initiates a protective T helper type 1 immune response
6. Tissue expression of inducible nitric oxide synthase is closely associated with resistance to Leishmania major
7. Class II major histocompatibility complex-deficient mice initially control an infection with Leishmania major but succumb to the disease
8. + T cells do not mediate a protective immune response
9. Protective role of CD40 in Leishmania major infection at two distinct phases of cell-mediated immunity
10. CD40 ligand is required for protective cell-mediated immunity to Leishmania major
11. + T cells in susceptible BALB/c as compared with resistant CBA mice
12. Role of T cell subsets during the recall of immunologic memory to Leishmania major
13. + T cells
14. + T cells following secondary infection of mice immune to Leishmania major
15. 2microglobulin-deficient mice fail to confirm a primary protective role for CD8 cells in experimental leishmaniasis
16. 2-microglobulin-deficient mice
17. Effective and long-lasting immunity against the parasite Leishmania major in CD8-deficient mice
18. The effect of post-bloodmeal nutrition of Phlebotomus papatasi on the transmission of Leishmania major
19. A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity
20. E-cadherin-mediated adhesion involving Langerhans cell-like dendritic cells expanded from murine fetal skin
21. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow
22. Development of a natural model of cutaneous leishmaniasis: Powerful effects of vector saliva and saliva preexposure on the long-term outcome of Leishmania major infection in the mouse ear dermis
23. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor Ab for sterile cure
24. Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: Implications for the initiation of anti-Leishmania immunity
25. + cytotoxic T cell responses
26. + T cells
27. Langerhans cells that have matured in vivo in the absence of T cells are fully capable of inducing a helper CD4 as well as a cytotoxic CD8 response
28. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules
29. + T cell responses to infectious agents, tumors, transplants, and vaccines
30. vβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
31. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells
32. IL-12p70 production by Leishmania major-harboring human dendritic cells is a CD40/CD40 ligand-dependent process
33. Langerhans cells transport Leishmania major from the infected skin to the draining lymph node for presentation to antigen-specific T cells
34. + immune T cells against toxoplasmosis in mice
35. A T cell clone directed at the circumsporozoite protein which protects mice against both Plasmodium yoelii and Plasmodium berghei
36. + T cells in immunity to malaria sporozoites
37. Isolation and characterization of protective cytolytic T cells in a rodent malaria model system
38. + cytotoxic T cells and Leishmania-infected macrophages
39. + T cells
40. CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines
41. + T cells are a biologically relevant source of macrophage inflammatory protein-1α in vivo
42. + T cells produce RANTES during acute rejection of murine allogeneic skin grafts
43. + T cells in pathogenesis associated with Leishmania amazonensis infection
44. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure
45. The evolution of the lesion in cutaneous leishmaniasis
46. In situ characterization of the cellular immune response in American cutaneous leishmaniasis
47. In situ characterization of the cutaneous immune response in Ethiopian cutaneous leishmaniasis
48. Cell populations in the lesion of human cutaneous leishmaniasis: A light microscopical, immunohistochemical and ultrastructural study
49. The pathology of cutaneous leishmaniasis due to Leishmania major in Sudan
50. Characterization of the local and systemic immune responses in patients with cutaneous leishmaniasis due to Leishmania major
51. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major
52. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection
53. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge